Revive Therapeutics Ltd
Change company Symbol lookup
Select an option...
RVVTF Revive Therapeutics Ltd
$ICEFSTS ICE FactSet Taiwan Core Semiconducto
UGRO Urban-Gro Inc
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
AGNCN AGNC Investment Corp
XJMMX Nuveen Multi-Market Income Fund Inc
THDDY TV Asahi Holdings Corp
ABCB Ameris Bancorp
NSAUF MegumaGold Corp
TSIBW Tishman Speyer Innovation Equity II Warrant Exp 11 Feb 2026 *W EXP 02/11/2026
Go

Health Care : Pharmaceuticals | Small Cap Growth
Based in Canada
Company profile

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and rare disorders. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Closing Price
$0.2183
Day's Change
-0.0337 (-13.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2503
Day's Low
0.212
Volume
(Heavy Day)
Volume:
914,786

10-day average volume:
649,762
914,786

Display:

Providers:

UpdateCancel
6 providers
January 19, 2022
Psilocybin and MDMA Get the Green Light for Medical Use in Canada

After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes. Canada's legislation now permits the use of psychedelics beyond palliative care, something...(PR Newswire)

January 18, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an...(Globe Newswire)

January 17, 2022
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV)...(Globe Newswire)

January 06, 2022
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, wishes to clarify...(Globe Newswire)

December 29, 2021
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide...(Globe Newswire)

December 03, 2021
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce...(Globe Newswire)

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce...(Globe Newswire)

November 23, 2021
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce...(Globe Newswire)

November 16, 2021
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a...(Globe Newswire)

November 03, 2021
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.